Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 2
1969 1
1970 2
1971 5
1972 4
1973 3
1974 6
1975 3
1976 2
1978 1
1979 2
1980 1
1981 2
1982 2
1983 1
1984 2
1985 1
1986 3
1987 2
1989 3
1990 7
1991 8
1992 14
1993 5
1994 23
1995 12
1996 12
1997 9
1998 18
1999 9
2000 12
2001 27
2002 10
2003 15
2004 25
2005 22
2006 16
2007 34
2008 43
2009 27
2010 40
2011 37
2012 27
2013 37
2014 38
2015 44
2016 41
2017 42
2018 32
2019 11
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

683 results
Results by year
Filters applied: . Clear all
Page 1
[Drug-induced dyspepsia].
Gross M and Labenz J. Dtsch Med Wochenschr 2015. PMID 25970411 German.
Patients often report upper abdominal pain, an early sense of satiety, epigastric discomfort or pain in the upper abdomen or behind the breastbone, flatulence, diarrhoea or constipation. ...Given the high frequency of these symptoms in the general population and the large number of medications many patients are taking, it can be very difficult in a given patient to differentiate between drug-induced side effects and spontaneously occurring symptoms....
Patients often report upper abdominal pain, an early sense of satiety, epigastric discomfort or pain in the upper abdomen or behind the brea …
Constipation and Botanical Medicines: An Overview.
Cirillo C and Capasso R. Phytother Res 2015 - Review. PMID 26171992
The causes of constipation are mainly three: lifestyle related (functional constipation), disease related, and drug induced. Constipation can generate considerable suffering, including abdominal pain and distension, anorexia, and nausea. The value of some therapeutic measures such as increased fluid intake, physical activity, diet rich in fiber, and nutritional supplements recommended for the relief of constipation is still questionable. ...
The causes of constipation are mainly three: lifestyle related (functional constipation), disease related, and drug
Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.
Nee J, et al. Clin Gastroenterol Hepatol 2018. PMID 29374616
BACKGROUND & AIMS: Opioid-induced constipation (OIC) is a common problem in patients on chronic opioid therapy for cancer-related and non-cancer-related pain. ...Participants who received μ-opioid-receptor antagonists were significantly more likely to have diarrhea, abdominal pain, nausea, or vomiting than patients who received placebo. ...
BACKGROUND & AIMS: Opioid-induced constipation (OIC) is a common problem in patients on chronic opioid therapy for cancer- …
The Ever-Changing Landscape of Drug-Induced Injury of the Lower Gastrointestinal Tract.
Marginean EC. Arch Pathol Lab Med 2016 - Review. PMID 27472233
CONTEXT: -There is an ever-growing armamentarium of pharmacologic agents that can cause gastrointestinal (GI) mucosal injury, the most common symptoms being diarrhea, constipation, nausea, and vomiting. ...It is important for the pathologist to keep in mind that a single drug type can induce many histologic patterns of mucosal injury that can mimic many disease entities. ...
CONTEXT: -There is an ever-growing armamentarium of pharmacologic agents that can cause gastrointestinal (GI) mucosal injury, the most commo …
Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders.
Cryer B, et al. Dig Dis Sci 2017. PMID 28849329 Free PMC article.
BACKGROUND: Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women. Lubiprostone is generally well tolerated, with nausea being the most common adverse event. AIMS: To characterize nausea with lubiprostone using pooled results from clinical studies in patients with CIC, OIC, or IBS-C. ...
BACKGROUND: Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) an …
Advances in pharmacotherapy for opioid-induced constipation - a systematic review.
Siemens W, et al. Expert Opin Pharmacother 2015 - Review. PMID 25539282
INTRODUCTION: Opioid-induced constipation (OIC) is one of the most frequent and burdening adverse events (AE) of opioid therapy. ...Besides nausea and diarrhea, abdominal pain was the most frequent AE for all drugs (risk ratio, range: 1.52 - 5.06) except for alvimopan. ...
INTRODUCTION: Opioid-induced constipation (OIC) is one of the most frequent and burdening adverse events (AE) of opioid therap …
The cost of opioid-related adverse drug events.
Kane-Gill SL, et al. J Pain Palliat Care Pharmacother 2014 - Review. PMID 25102043
Opioids are the cornerstone of pain management; however, their use is associated with a variety of adverse drug events (ADEs) ranging from nausea and vomiting to urinary retention and respiratory depression. ...Nausea, vomiting, and constipation are frequent and increased costs occur in all types of pain (surgical, nonsurgical, cancer, noncancer) in both inpatients and outpatients. ...
Opioids are the cornerstone of pain management; however, their use is associated with a variety of adverse drug events (ADEs) ranging …
Opioid Induced Constipation.
Sizar O and Gupta M. StatPearls. StatPearls Publishing 2019 Jan– - Review. PMID 29630236 Free Books and Documents.
In association with constipation, patients may also develop other GI side effects like nausea, vomiting, bloat, abdominal pain, and straining. Many patients who develop constipation following opioids stop the drug therapy because they simply cannot tolerate the adverse effects on the GI tract. ...
In association with constipation, patients may also develop other GI side effects like nausea, vomiting, bloat, abdominal pain …
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.
Wang W, et al. Medicine (Baltimore) 2018. PMID 30212982 Free PMC article.
Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea, anxiety, and insomnia. This study was conducted to evaluate the efficacy of olanzapine (5 mg) combined with 5-HT3 receptor antagonists and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in lung patients receiving cisplatin-based (25 mg/m2 d1-3) highly emetogenic chemotherapy (HEC).Olanzapine (5 mg) was administered a day prior to cisplatin administration and continued on days 1 to 5. ...The main side effects were grade 1 somnolence (35.0%) and mild constipation (52.5%).Around 5 mg olanzapine may be used as a potential, safe, and cost-beneficial alternative to prevent nausea and vomiting for HEC, particular for multiday chemotherapy regimen....
Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea, anxiety, and insomnia. This study was co …
The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review
Mercadante S. Curr Med Res Opin 2017 - Review. PMID 28906155
Tapentadol, when used at ≥60 mg of oral morphine equivalents in opioid-tolerant patients with cancer pain, or passing from step-2 doses to ≥60 mg of oral morphine equivalents, was well tolerated and effective and could be considered as a flexible drug to be used for the management of moderate-to-severe cancer pain. The limited occurrence of gastrointestinal adverse effects may be a great advantage in the context of a disease like cancer, where multiple causes contribute to nausea, vomiting, or constipation; however, studies of tapentadol given at doses equivalent to step-3 level have some weaknesses, as data from prospective observational studies are poorly generalizable due to a small number of participants, controlled studies do not clearly show a superiority of tapentadol with respect to other opioids, and the sample size is often small. ...
Tapentadol, when used at ≥60 mg of oral morphine equivalents in opioid-tolerant patients with cancer pain, or passing from step-2 doses to ≥ …
683 results
Jump to page
Feedback